[2] Ma, X. et al. Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic β-cells". Journal of Diabetes. 2014, 6, 394–402. [3] Gautier, J. F. et al. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes & Metabolism....
根据美国糖尿病协会发布的 《Standards of Medical Care in Diabetes-2023》,降糖药物主要被分为 8 类分别为二甲双 胍、SGLT-2 抑制剂、GLP-1 受体激动剂、GIP/GLP-1 受体激动剂、DPP-4 抑制剂、噻唑 烷二酮类、磺脲类和胰岛素。从降糖效果看,GLP-1 受体激动剂、GIP/GLP-受体激动剂 和胰岛素的效果最优,...
SGLT2 & GLP-1 in Diabetes你可能也喜歡 Metabolic Diseases 醫藥 Kabyier - Doctor 醫藥 Hydrocephalus Procedure 健康與健身 Kabyier - Patient 醫藥 CVMedical: HeartFailure 醫藥
于是,约翰·恩博士在1996年的American Diabetes Association Annual Meeting/美国糖尿病协会年会上,用海报(是的,他当时并没有获得发言机会)展示了Exendin-4在糖尿病小鼠中的“长效”作用。 Amylin病理学总监Andrew Young在会场看到了约翰·恩博士的展示,并非常清楚其价值,因为他们自己正在研发“长效”GLP-1类似物却一直...
al. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes &...
Dulaglutide是一种注射GLP-1受体激动剂,根据REWIND(Researching Cardiovascular Events With a Weekly Incretin in Diabetes)研究报道,该药物可预防初级和二级中年和老年2型糖尿病患者的心血管风险(CV)。 REWIND研究是第一个包含大多数参与者(69%)的研究,他们在登记时没有心血管疾病史。该试验的中位随访时间超过5年,...
利拉鲁肽对糖 验显示,利拉鲁肽1.2mg/d和1.8mg/d单药治疗分 尿病的影响和作用 :心血管预后结果的评估 别使 T2DM 患者的收缩压降低 2.1mmHg 和 (Liraglutide Effect and Action in Diabetes: 3.6mmHg[3];度拉糖肽0.75mg和1.5mg(每周1次) Evaluation of cardiovascular outcome Results, 单药治疗分别使 T2DM...
Understanding RVO 教育 Medical Management of Melanoma Antiarrhythmics for Afib 教育 Non-Small-Cell Lung Cancer Familial Hypercholesterolemia Anti-VEGF’s in DR, AMD & RVO Covid Frontline AR 醫藥 Individualizing Diabetes Care DR & PRP Therapy 醫藥...
资料1、LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept 资料2、The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, ...
mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a ...